169 related articles for article (PubMed ID: 20570038)
21. Autoimmune inflammation from the Th17 perspective.
Furuzawa-Carballeda J; Vargas-Rojas MI; Cabral AR
Autoimmun Rev; 2007 Jan; 6(3):169-75. PubMed ID: 17289553
[TBL] [Abstract][Full Text] [Related]
22. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
[TBL] [Abstract][Full Text] [Related]
23. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.
Zhang X; Tao Y; Wang J; Garcia-Mata R; Markovic-Plese S
Eur J Immunol; 2013 Jan; 43(1):281-9. PubMed ID: 23076801
[TBL] [Abstract][Full Text] [Related]
24. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
[TBL] [Abstract][Full Text] [Related]
25. Memory and naïve B-cell subsets in patients with multiple sclerosis.
Niino M; Hirotani M; Miyazaki Y; Sasaki H
Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
[TBL] [Abstract][Full Text] [Related]
26. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM
Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486
[TBL] [Abstract][Full Text] [Related]
27. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
Huber M; Heink S; Grothe H; Guralnik A; Reinhard K; Elflein K; Hünig T; Mittrücker HW; Brüstle A; Kamradt T; Lohoff M
Eur J Immunol; 2009 Jul; 39(7):1716-25. PubMed ID: 19544308
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
[TBL] [Abstract][Full Text] [Related]
29. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.
Lombardi V; Van Overtvelt L; Horiot S; Moingeon P
J Immunol; 2009 Mar; 182(6):3372-9. PubMed ID: 19265114
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon β-1 therapy.
Esendagli G; Kurne AT; Sayat G; Kilic AK; Guc D; Karabudak R
J Neuroimmunol; 2013 Feb; 255(1-2):81-4. PubMed ID: 23177721
[TBL] [Abstract][Full Text] [Related]
31. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells.
Santarlasci V; Maggi L; Capone M; Frosali F; Querci V; De Palma R; Liotta F; Cosmi L; Maggi E; Romagnani S; Annunziato F
Eur J Immunol; 2009 Jan; 39(1):207-15. PubMed ID: 19130583
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.
Sutton CE; Lalor SJ; Sweeney CM; Brereton CF; Lavelle EC; Mills KH
Immunity; 2009 Aug; 31(2):331-41. PubMed ID: 19682929
[TBL] [Abstract][Full Text] [Related]
35. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
Giacomini E; Severa M; Rizzo F; Mechelli R; Annibali V; Ristori G; Riccieri V; Salvetti M; Coccia EM
Eur J Immunol; 2013 Jul; 43(7):1963-72. PubMed ID: 23636665
[TBL] [Abstract][Full Text] [Related]
36. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23.
Morishima N; Mizoguchi I; Takeda K; Mizuguchi J; Yoshimoto T
Biochem Biophys Res Commun; 2009 Aug; 386(1):105-10. PubMed ID: 19501566
[TBL] [Abstract][Full Text] [Related]
37. Th17 cell induction and immune regulatory effects.
Bi Y; Liu G; Yang R
J Cell Physiol; 2007 May; 211(2):273-8. PubMed ID: 17311299
[TBL] [Abstract][Full Text] [Related]
38. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
[TBL] [Abstract][Full Text] [Related]
39. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
[TBL] [Abstract][Full Text] [Related]
40. TLR2-activated human langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23.
Aliahmadi E; Gramlich R; Grützkau A; Hitzler M; Krüger M; Baumgrass R; Schreiner M; Wittig B; Wanner R; Peiser M
Eur J Immunol; 2009 May; 39(5):1221-30. PubMed ID: 19350551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
